Comparative Diagnostic Value Between 18F-FDG and 18F-DCFPyL PET/CT in Recurrent or Metastasis Clear Cell Renal Carcinoma after Nephrectomy

G Wang, Y Liu, H Dang, Y Wu, M Lin, S Yao, J Tian… - 2021 - Soc Nuclear Med
1355 Objectives: Although the role of 18 F-fluoro-2-deoxy-2-d-glucose (18 F-FDG) PET/CT
(positron emission tomography/computed tomography) in diagnosing renal cell carcinoma …

Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: Preliminary results of 15 patients

Y Liu, G Wang, H Yu, Y Wu, M Lin… - Nuclear Medicine …, 2020 - journals.lww.com
Objectives This study aimed to compare the diagnostic performance of 18 F-DCFPyL and 2-
deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET/computed tomography in the restaging of …

To access the clinical value of combined 18F-FDG and 18F-DCFPyL PET/CT in postoperative recurrent or metastasis renal cell carcinoma

G Wang, Y Liu, J Ning, M Lin, Y Wu, B Xu, J Gao - 2020 - Soc Nuclear Med
478 Objectives: Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG),
although not part of the standard protocol in RCC staging, shows promise for restaging and …

[HTML][HTML] Role of 18F-FDG PET/CT in post-operative assessment and therapeutic follow up of renal cell carcinoma

TW Kassem, NK Ramadan, SAZ Hanna - The Egyptian Journal of …, 2018 - Elsevier
Objective The aim of this study was to evaluate the role of PET/CT in post-operative
assessment and therapeutic follow up of renal cell carcinoma (RCC). Patients and methods …

Restaging clear cell renal carcinoma with 18F-FDG PET/CT

C Fuccio, F Ceci, P Castellucci… - Clinical Nuclear …, 2014 - journals.lww.com
Aim The aim of our retrospective study was to assess the usefulness of 18 F-FDG PET/CT in
the restaging of clear cell renal cell carcinoma (RCC) patients. Patients and Methods Sixty …

[HTML][HTML] 18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cancer?

L Evangelista, L Cuppari - Clinical and Translational Imaging, 2018 - Springer
Radiolabeled (either 68Ga or 18F) prostate-specific membrane antigen (PSMA) for positron
emission tomography (PET) imaging has been extensively used in patients with prostate …

Role of FDG PET-CT in recurrent renal cell carcinoma

R Kumar, V Shandal, SA Shamim, S Jeph… - Nuclear Medicine …, 2010 - journals.lww.com
Aim To determine the efficacy of positron emission tomography-computed tomography using
F-18 fluoro-deoxy-glucose (F-18 FDG PET-CT) in diagnosing the recurrence of renal cell …

Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma

F Bertagna, F Motta, M Bertoli, G Bosio… - Nuclear Medicine …, 2013 - journals.viamedica.pl
BACKGROUND: Renal cancers account for around 3% of all cancers and the most common
type of (90%) is renal cell carcinoma Five-year survival rate in renal cancer patients is …

Significance of 18F‐fluorodeoxyglucose positron‐emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma

JW Park, MK Jo, HM Lee - BJU international, 2009 - Wiley Online Library
OBJECTIVES To evaluate the role of 18F‐fluorodeoxyglucose (FDG) positron‐emission
tomography (PET)/computed tomography (CT) for the surveillance of patients with renal cell …

[HTML][HTML] Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma—are we underusing PET/CT?

M Pereira, CB Punatar, N Singh… - Diagnostic and …, 2022 - ncbi.nlm.nih.gov
PURPOSE The aim of this study was to compare 18 F-fluorodeoxyglucose positron emission
tomography–computed tomography (18 F-FDG PET/CT) scan with computed tomography …